{'fraction_non_alphanumeric': 0.030542986425339366, 'fraction_numerical': 0.021493212669683258, 'mean_word_length': 4.822368421052632, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Clinical and microbiological study of enduracidin in infections due to methicillin-resistant strains of Staphylococcus aureus.

Enduracidin, administered in doses of 100 mg i.m. every 12 hours for about 10 days, to 20 patients suffering from infections due to methicillin-resistant strains of Staphylococcus aureus, eliminated the microorganism in 8 cases of urinary tract infections, in 4 out of 9 cases of dermatological infections, and in none of 3 cases of chronic osseous infections. No toxic phenomenon or side-effect was observed. No increased resistance of the strains was noted in course of treatment. The blood levels, of the order of 0.5 μg/ml, 2 and 6 h after the first injection, were higher at the end of treatment (2–3 μg/ml), bearing witness to an accumulation phenomenon. The bactericidal activity of the patients’ sera is directly related to their enduracidin level.